Heidelberg Pharma AG (WBO:HPHA) ROCE %: 16.76% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HPHA Heidelberg Pharma AG WBO:HPHA
32 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG ROCE %?

Heidelberg Pharma AG WBO:HPHA 32 ROCE % is 16.76% as of May. 2026. GuruFocus rates WBO:HPHA with a GF Score™ of 32/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Heidelberg Pharma AG's annualized ROCE % for the quarter that ended in May. 2026 was 16.76%.

Heidelberg Pharma AG  (WBO:HPHA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Heidelberg Pharma AG ROCE % Related Terms

Heidelberg Pharma AG ROCE % Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG ROCE % Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -259.33 -42.66 -31.79 -37.25 -103.52

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.50 -65.63 -218.18 -70.26 16.76
WBO:HPHA
32GF Score
Heidelberg Pharma AG WBO:HPHA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG ROCE % Calculation

Heidelberg Pharma AG's annualized ROCE % for the fiscal year that ended in Nov. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Nov. 2025 )  (A: Nov. 2024 )(A: Nov. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Nov. 2025 )  (A: Nov. 2024 )(A: Nov. 2025 )
=-41.226/( ( (60.72 - 7.997) + (38.136 - 11.21) )/ 2 )
=-41.226/( (52.723+26.926)/ 2 )
=-41.226/39.8245
=-103.52 %

Heidelberg Pharma AG's ROCE % of for the quarter that ended in May. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: May. 2026 )  (Q: Feb. 2026 )(Q: May. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: May. 2026 )  (Q: Feb. 2026 )(Q: May. 2026 )
=5.152/( ( (30.778 - 9.03) + (46.895 - 7.158) )/ 2 )
=5.152/( ( 21.748 + 39.737 )/ 2 )
=5.152/30.7425
=16.76 %

(1) Note: The EBIT data used here is four times the quarterly (May. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.76% mean?
Heidelberg Pharma AG (WBO:HPHA) has a ROCE % of 16.76% as of May. 2026.
Is Heidelberg Pharma AG's ROCE % too high?
Heidelberg Pharma AG's current ROCE % is 16.76%. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's ROCE % compare to VRTX and REGN?
Heidelberg Pharma AG's ROCE % of 16.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Heidelberg Pharma AG's current ROCE % is 16.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current ROCE % is 16.76%. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current ROCE % is 16.76% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for WBO:HPHA:

  • ROCE %: 16.76%
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Germany
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score

Get the complete analysis for WBO:HPHA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value